Phenotypes Associated with This Genotype

Genotype
MGI:5304758

• Allelic Composition: Col1a1^{tm2(tetO-RNAi:Rps19)Karl}/Col1a1^{tm2(tetO-RNAi:Rps19)Karl}; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}
• Genetic Background: involves: 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:179085 )

• most mice die within 2 months following doxycycline treatment

hematopoietic system

macrocytosis ( J:179085 )

• seven weeks after doxycycline treatment

thrombocytosis ( J:179085 )

• two weeks after doxycycline treatment

decreased hematopoietic cell number ( J:179085 )

decreased erythrocyte cell number ( J:179085 )

• two and seven weeks after doxycycline treatment

decreased neutrophil cell number ( J:179085 )

• seven weeks after doxycycline treatment

thrombocytopenia ( J:179085 )

• seven weeks after doxycycline treatment

decreased lymphocyte cell number ( J:179085 )

• two and seven weeks after doxycycline treatment

reticulocytopenia ( J:179085 )

• two weeks after doxycycline treatment

growth/size/body

postnatal growth retardation ( J:179085 )

• following doxycycline treatment

immune system

decreased neutrophil cell number ( J:179085 )

• seven weeks after doxycycline treatment

decreased lymphocyte cell number ( J:179085 )

• two and seven weeks after doxycycline treatment

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Diamond-Blackfan anemia		DOID:1339	OMIM:PS105650	J:179085